» Articles » PMID: 15753403

Activated Marrow-infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors

Overview
Journal Cancer Res
Specialty Oncology
Date 2005 Mar 9
PMID 15753403
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

A major limitation of adoptive immunotherapy is the availability of T cells specific for both terminally differentiated tumor cells and their clonogenic precursors. We show here that marrow-infiltrating lymphocytes (MILs) recognize myeloma cells after activation with anti-CD3/CD28 beads with higher frequency than activated peripheral blood lymphocytes from the same patients. Furthermore, activated MILs target both the terminally differentiated CD138+ plasma cells and the myeloma precursor as shown by profound inhibition in a tumor clonogenic assay. The presence of antigen in the marrow microenvironment seems to be important for the maintenance of tumor specificity. Taken together, these results highlight the intrinsic tumor specificity of MILs and describe a novel approach for the generation of tumor-specific T-cell populations suitable for adoptive immunotherapy of multiple myeloma.

Citing Articles

Exploring cellular immunotherapy platforms in multiple myeloma.

Vo M, Jung S, Nguyen V, Tran V, Ruzimurodov N, Kim S Heliyon. 2024; 10(6):e27892.

PMID: 38524535 PMC: 10957441. DOI: 10.1016/j.heliyon.2024.e27892.


The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception.

Dhodapkar M Am J Hematol. 2022; 98 Suppl 2:S4-S12.

PMID: 36194782 PMC: 9918687. DOI: 10.1002/ajh.26752.


Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.

Welters C, Lammoglia Cobo M, Stein C, Hsu M, Ben Hamza A, Penter L Cancer Immunol Res. 2022; 10(11):1407-1419.

PMID: 36122410 PMC: 9627264. DOI: 10.1158/2326-6066.CIR-22-0434.


T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments.

Simmons G, Castaneda Puglianini O Cancers (Basel). 2022; 14(17).

PMID: 36077787 PMC: 9455067. DOI: 10.3390/cancers14174249.


Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.

Chung D, Sharma S, Rangesa M, DeWolf S, Elhanati Y, Perica K Blood Adv. 2022; 6(5):1547-1558.

PMID: 35100339 PMC: 8905697. DOI: 10.1182/bloodadvances.2021005941.